CO-1686: Phase I/II ongoing

Clovis began dosing patients with a hydrobromide salt tablet formulation of CO-1686 in an ongoing, dose-escalation Phase I portion of an open-label, international Phase I/II trial. Current patients will transition to the hydrobromide salt tablet from the free base capsule formulation. The trial is evaluating twice-daily CO-1686 in 21-day cycles in about 70 patients who have progressed on prior EGFR-directed tyrosine kinase inhibitor (TKI) therapy. Clovis said the new formulation of CO-1686 improves absorption and reduces exposure variability compared to the free base capsule formulation (see BioCentury, May 13). ...